Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model

• Published in: Scientific reports Vol. 13; no. 1; p. 11361
• Main Authors: Watanabe, Hiromitsu, Matsushita, Yuto, Tamura, Keita, Motoyama, Daisuke, Sugiyama, Takayuki, Otsuka, Atsushi, Miyake, Hideaki
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13.07.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 692/4025; 692/4028; Apoptosis; Axitinib - therapeutic use; Carcinoma, Renal Cell - pathology; CD11b antigen; CD3 antigen; CD8 antigen; Combined treatment; Humanities and Social Sciences; Humans; Immune checkpoint inhibitors; Injection; Intravenous administration; Kidney cancer; Kidney Neoplasms - pathology; Lymphocytes; Lymphocytes T; multidisciplinary; PD-1 protein; PD-L1 protein; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase; Renal cell carcinoma; Science; Science (multidisciplinary); Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-37857-9

Recently, several types of systemic therapy using tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) have been performed for advanced renal cell carcinoma (aRCC) patients; however, the optimal strategy of sequential treatment with these agents has not been well established. The objective of this study was to determine the differences of therapeutic effects according to timing for the introduction of TKI and ICI using a mouse RCC, RenCa model. The effects of combined treatment of TKI and/or ICI with axitinib, anti-mouse programmed death (PD)-1, or PD-ligand 1 (PD-L1) antibody on tumor growth and survival after subcutaneous and intravenous injection of RenCa cells, respectively, were compared according to three different treatment schedules: simultaneous administration, initial axitinib administration, and initial ICI administration. Infiltrating patterns of lymphocytes into tumors after combined treatments were evaluated by immunohistochemical staining. In mice treated with anti-PD-1 and anti-PD-L1 antibodies, significantly marked inhibitory effects on subcutaneous growth of tumors were observed in the simultaneous and initial ICI treatment groups, but not the group with the initial axitinib administration, compared to controls without treatment. Survival intervals of mice after intravenous injection of RenCa cells were significantly longer in the simultaneous and initial ICI administration, but not the initial axitinib administration, compared to the control. Furthermore, both CD8+ to CD3+ and CD8+ to CD11b+ T-lymphocyte ratios in subcutaneous RenCa tumors were significantly higher in the simultaneous and initial ICI administration, but not the initial axitinib administration, compared to the control. Favorable control against aRCC progression may be achieved by administering TKI and ICI simultaneously or ICI followed by TKI.